On December 4, 2012, Chelsea Therapeutics International, Ltd. (the "Company") issued a press release announcing the results of Study 306B, the Company's Phase III trial evaluating the efficacy of Northera™ (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension associated with Parkinson's Disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On December 4, 2012, the Company also hosted a conference call and webcast to discuss the Study 306B results. A copy of the slide presentation included in the webcast is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

(d) Exhibits

Exhibit No. Description

  99.1         Press release dated December 4, 2012.

  99.2         PowerPoint presentation of December 4, 2012.







                                   Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ J. Nick Riehle
J. Nick Riehle
Chief Financial Officer

Dated: December 5, 2012